Bayesian Health Receives First FDA Clearance for Continuous AI Sepsis Monitoring

Bayesian Health has received FDA 510(k) clearance for its continuous AI sepsis monitoring device, announced in a press release. This marks the first time the U.S. regulator has cleared a continuous AI system for sepsis detection.

The cleared device operates as part of Bayesian Health’s clinical intelligence platform, which monitors hospitalized patients in real time and flags those showing early signs of sepsis. The platform integrates with electronic health records to surface actionable insights within existing clinical workflows.

According to the company, the system continuously evaluates patient data to detect deterioration before clinical suspicion arises. Validation studies cited included over 760,000 patient encounters across multiple hospitals, showing earlier detection and reduced mortality when clinicians acted on its alerts.

The FDA clearance positions Bayesian Health to seek reimbursement under the Centers for Medicare and Medicaid Services' New Technology Add-on Payment program, with a decision expected in August 2026. The sepsis flagging device is part of a broader platform aimed at identifying early signs of conditions such as respiratory failure and cardiac events.